Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)

PURPOSE: To illustrate the benefits of the extended half-life (EHL) recombinant factor VIII product N8-GP (Esperoct(®), turoctocog alfa pegol) by describing individual cases of patients with severe hemophilia A treated with N8-GP in the pathfinder clinical trial program. PATIENTS AND METHODS: This m...

Descripción completa

Detalles Bibliográficos
Autores principales: Klamroth, Robert, Hampton, Kingsley, Saulyte Trakymienė, Sonata, Korsholm, Lars, Carcao, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575374/
https://www.ncbi.nlm.nih.gov/pubmed/34764641
http://dx.doi.org/10.2147/PPA.S326282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575374/
https://www.ncbi.nlm.nih.gov/pubmed/34764641
http://dx.doi.org/10.2147/PPA.S326282

Ejemplares similares